Skip to main content
Clinical Trials/DRKS00015034
DRKS00015034
Completed
未知

Evaluation of Hemostatics in coagulation inhibited human blood with viscoelastic testing (ROTEM) - HemPIC (Hemostatics in Patients with Inhibited Coagulation)

Bundeswehrkrankenhaus UlmKlinik für Anästhesie und IntensivmedizinSektion Notfallmedizin0 sites40 target enrollmentOctober 26, 2018

Overview

Phase
未知
Intervention
Not specified
Conditions
R58
Sponsor
Bundeswehrkrankenhaus UlmKlinik für Anästhesie und IntensivmedizinSektion Notfallmedizin
Enrollment
40
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 26, 2018
End Date
March 19, 2022
Last Updated
last year
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Bundeswehrkrankenhaus UlmKlinik für Anästhesie und IntensivmedizinSektion Notfallmedizin

Eligibility Criteria

Inclusion Criteria

  • Control group:
  • \- Healthy, especially concerning coagulation
  • \- Informed consent
  • Intervention group:
  • \- Regular medication of one of the following medications: Phenprocoumon, Enoxaparin, acetylsalicylic acid and Ticagrelor (combination), Dabigatran, Apixaban
  • \- Informed consent
  • \- Heparin Group: surgery with a mandatory heparin application during surgery

Exclusion Criteria

  • Control group:
  • \- Bleeding disorders (e.g. haemophilia, factor 5 Leiden mutation)
  • \- Medications within the last 10 days
  • \- Regular medication
  • \- Missing informed consent
  • \- Malignancies of the haematopoietic system
  • \- Status after diseases which caused a stay at hospital or doctor’s consultation during the last 14 days
  • \- HES \> 1,5 l during the past 4 weeks
  • Intervention group:
  • \- Regular medication of more than one of the following: Phenprocoumon, Enoxaparin, acetylsalicylic acid and Ticagrelor, Dabigatran, Apixaban, acetylsalicylic acid

Outcomes

Primary Outcomes

Not specified

Similar Trials